Clinical trial data for tenapanor for management of hyperphosphataemia in dialysis patients presented at the Annual Meeting of the American Society of Nephrology
Results from the Phase III PHREEDOM study show a difference of 1.4mg/dL in least squares mean change in serum phosphorous from the end of an open-label randomised treatment period to the end of a 12-week randomised placebo-controlled withdrawal period (p<0.0001; primary endpoint)
Source:
Biospace Inc.
SPS commentary:
Tenapanor is a first-in-class phosphate absorption inhibitor currently under review in the US (no review as yet underway in Europe/UK). Poster presentations discussing results from the PHREEDOM, BLOCK and AMPLIFY Phase III trials are now available to access from the conference website.